Cardiac arrest & resuscitation
Interleukin 6 blockage alters the plasma metabolome in out-of-hospital cardiac arrest
Authors' conclusion
Blocking the IL-6 receptor with tocilizumab early after OHCA impacts circulating metabolites, particularly those within the glycine, serine, and threonine pathways, highlighting the connection between acute systemic inflammation and metabolism.
Study context
- Population
- Comatose patients resuscitated from out-of-hospital cardiac arrest (OHCA)85 randomised
- Participants
- 80 patients
- Comparison
- Tocilizumab vs placebo
- Tocilizumabn = 39
- Placebon = 41reference
- Primary endpoint
- Early effects of tocilizumab on circulating metabolite levels
- Follow-up
- 48 h
Methodological detailsmetabolomics substudy, double-blind, targeted metabolomics (60 metabolites)
- Metabolomics substudy
- Double-blind
- Targeted metabolomics (60 metabolites)
Primary result
As reported in the abstract
Plasma metabolites
- Tocilizumab increased plasma amino acids, especially threonine, glycine and serine, by more than a factor of 1.5
- p < 0.01
- 15(S)-HETE and 12(S)-HETE 1.9 times higher
- p < 0.01
Further findings
Tricarboxylic acid (TCA) cycle metabolites at hospital arrival
- Associated with time to return of spontaneous circulation and independently with early IL-6 levels
- all p < 0.05
Early medium-chain acylcarnitines
- Associated with age, NT-proBNP, eGFR and neurofilament light chain
- all p < 0.01
Original publication
Interleukin 6 blockage alters the plasma metabolome in out-of-hospital cardiac arrest. Resuscitation. Published 5 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →